{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:06:17Z","timestamp":1792724777797,"version":"4.5.0"},"reference-count":60,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>T cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy of immature T\u00a0lymphocytes, associated with higher rates of induction failure compared with those in B cell acute lymphoblastic leukemia. The potent immunotherapeutic approaches applied in B cell acute lymphoblastic leukemia, which have revolutionized the treatment paradigm, have proven more challenging in T-ALL, largely due to a lack of target antigens expressed on malignant but not healthy T cells. Unlike B cell depletion, T-cell aplasia is highly toxic. Here, we show that the chemokine receptor CCR9 is expressed in &amp;gt;70% of cases of T-ALL, including &amp;gt;85% of relapsed\/refractory disease, and only on a small fraction (&amp;lt;5%) of normal T cells. Using cell line models and patient-derived xenografts, we found that chimeric antigen receptor (CAR) T-cells targeting CCR9 are resistant to fratricide and have potent antileukemic activity both in vitro and in vivo, even at low target antigen density. We propose that anti-CCR9 CAR-T cells could be a highly effective treatment strategy for T-ALL, avoiding T cell aplasia and the need for genome engineering that complicate other approaches.<\/jats:p>","DOI":"10.1182\/blood.2021013648","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T13:53:01Z","timestamp":1651672381000},"page":"25-37","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":66,"title":["Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9757-8073","authenticated-orcid":false,"given":"Paul M.","family":"Maciocia","sequence":"first","affiliation":[{"name":"1Department of Haematology, Cancer Institute, University College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrycja A.","family":"Wawrzyniecka","sequence":"additional","affiliation":[{"name":"1Department of Haematology, Cancer Institute, University College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola C.","family":"Maciocia","sequence":"additional","affiliation":[{"name":"1Department of Haematology, Cancer Institute, University College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3074-6439","authenticated-orcid":false,"given":"Amy","family":"Burley","sequence":"additional","affiliation":[{"name":"1Department of Haematology, Cancer Institute, University College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thaneswari","family":"Karpanasamy","sequence":"additional","affiliation":[{"name":"1Department of Haematology, Cancer Institute, University College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Devereaux","sequence":"additional","affiliation":[{"name":"1Department of Haematology, Cancer Institute, University College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malika","family":"Hoekx","sequence":"additional","affiliation":[{"name":"1Department of Haematology, Cancer Institute, University College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3542-5976","authenticated-orcid":false,"given":"David","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"1Department of Haematology, Cancer Institute, University College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Leon","sequence":"additional","affiliation":[{"name":"1Department of Haematology, Cancer Institute, University College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Rapoz-D\u2019Silva","sequence":"additional","affiliation":[{"name":"1Department of Haematology, Cancer Institute, University College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0051-1965","authenticated-orcid":false,"given":"Rachael","family":"Pocock","sequence":"additional","affiliation":[{"name":"1Department of Haematology, Cancer Institute, University College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunniyat","family":"Rahman","sequence":"additional","affiliation":[{"name":"1Department of Haematology, Cancer Institute, University College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Gritti","sequence":"additional","affiliation":[{"name":"2Department of Haematology, Ospedale Papa Giovanni XXIII, Bergamo, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana C.","family":"Y\u00e1nez","sequence":"additional","affiliation":[{"name":"3Great Ormond Street Institute of Child Health, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Ross","sequence":"additional","affiliation":[{"name":"3Great Ormond Street Institute of Child Health, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Crompton","sequence":"additional","affiliation":[{"name":"3Great Ormond Street Institute of Child Health, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen","family":"Williams","sequence":"additional","affiliation":[{"name":"3Great Ormond Street Institute of Child Health, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Lee","sequence":"additional","affiliation":[{"name":"1Department of Haematology, Cancer Institute, University College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8347-9867","authenticated-orcid":false,"given":"Martin A.","family":"Pule","sequence":"additional","affiliation":[{"name":"1Department of Haematology, Cancer Institute, University College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc R.","family":"Mansour","sequence":"additional","affiliation":[{"name":"1Department of Haematology, Cancer Institute, University College London, London, United Kingdom;"},{"name":"3Great Ormond Street Institute of Child Health, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"25","key":"2022070715214982200_B1","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2009-08-231217","article-title":"T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII\/ECOG 2993)","volume":"114","author":"Marks","year":"2009","journal-title":"Blood."},{"issue":"7","key":"2022070715214982200_B2","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1182\/blood-2014-10-551895","article-title":"How I treat T-cell acute lymphoblastic leukemia in adults","volume":"126","author":"Litzow","year":"2015","journal-title":"Blood."},{"issue":"1","key":"2022070715214982200_B3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1200\/JCO.2017.74.0449","article-title":"Genotype-specific minimal residual disease interpretation improves stratification in pediatric acute lymphoblastic leukemia","volume":"36","author":"O\u2019Connor","year":"2018","journal-title":"J Clin Oncol."},{"issue":"3","key":"2022070715214982200_B4","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1470-2045(12)70600-9","article-title":"Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial","volume":"14","author":"Vora","year":"2013","journal-title":"Lancet Oncol."},{"issue":"8","key":"2022070715214982200_B5","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1182\/blood-2011-03-338707","article-title":"Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study","volume":"118","author":"Schrappe","year":"2011","journal-title":"Blood."},{"issue":"4","key":"2022070715214982200_B6","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","article-title":"In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation\/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII\/ECOG E2993)","volume":"111","author":"Goldstone","year":"2008","journal-title":"Blood."},{"issue":"4","key":"2022070715214982200_B7","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2141.2012.09095.x","article-title":"Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII\/ECOG2993 trial","volume":"157","author":"Sive","year":"2012","journal-title":"Br J Haematol."},{"issue":"3","key":"2022070715214982200_B8","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood."},{"issue":"4","key":"2022070715214982200_B9","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1200\/JCO.2009.22.2950","article-title":"Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study","volume":"28","author":"Ko","year":"2010","journal-title":"J Clin Oncol."},{"issue":"9","key":"2022070715214982200_B10","doi-asserted-by":"crossref","first-page":"E245","DOI":"10.1002\/ajh.25896","article-title":"Outcome of adults with relapsed\/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma","volume":"95","author":"Samra","year":"2020","journal-title":"Am J Hematol."},{"issue":"9","key":"2022070715214982200_B11","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med."},{"issue":"9","key":"2022070715214982200_B12","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA."},{"issue":"9","key":"2022070715214982200_B13","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2021.0987","article-title":"Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Locatelli","year":"2021","journal-title":"JAMA."},{"issue":"8","key":"2022070715214982200_B14","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med."},{"issue":"5","key":"2022070715214982200_B15","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med."},{"issue":"9","key":"2022070715214982200_B16","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat Med."},{"issue":"4","key":"2022070715214982200_B17","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nri.2016.28","article-title":"Human RAG mutations: biochemistry and clinical implications","volume":"16","author":"Notarangelo","year":"2016","journal-title":"Nat Rev Immunol."},{"issue":"3","key":"2022070715214982200_B18","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood."},{"issue":"6","key":"2022070715214982200_B19","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.4049\/jimmunol.168.6.2811","article-title":"A role for CCR9 in T lymphocyte development and migration","volume":"168","author":"Uehara","year":"2002","journal-title":"J Immunol."},{"issue":"9","key":"2022070715214982200_B20","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1182\/blood.V98.9.2626","article-title":"Mice lacking the CCR9 CC-chemokine receptor show a mild impairment of early T- and B-cell development and a reduction in T-cell receptor gammadelta(+) gut intraepithelial lymphocytes","volume":"98","author":"Wurbel","year":"2001","journal-title":"Blood."},{"issue":"12","key":"2022070715214982200_B21","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/nm.4444","article-title":"Targeting the T cell receptor \u03b2-chain constant region for immunotherapy of T cell malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat Med."},{"issue":"2","key":"2022070715214982200_B22","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41375-021-01385-0","article-title":"Chimeric antigen receptor T cells for gamma\u2013delta T cell malignancies","volume":"36","author":"Wawrzyniecka","year":"2022","journal-title":"Leukemia."},{"issue":"6352","key":"2022070715214982200_B23","doi-asserted-by":"crossref","first-page":"eaan2507","DOI":"10.1126\/science.aan2507","article-title":"A pathology atlas of the human cancer transcriptome","volume":"357","author":"Uhlen","year":"2017","journal-title":"Science."},{"issue":"8","key":"2022070715214982200_B24","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/ng.3909","article-title":"The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia","volume":"49","author":"Liu","year":"2017","journal-title":"Nat Genet."},{"issue":"4","key":"2022070715214982200_B25","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia."},{"issue":"8","key":"2022070715214982200_B26","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1182\/blood-2014-01-545020","article-title":"A highly compact epitope-based marker\/ suicide gene for easier and safer T-cell therapy","volume":"124","author":"Philip","year":"2014","journal-title":"Blood."},{"issue":"12","key":"2022070715214982200_B27","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2006-11-056754","article-title":"Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801","volume":"109","author":"DeAngelo","year":"2007","journal-title":"Blood."},{"issue":"7","key":"2022070715214982200_B28","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.bbmt.2017.04.003","article-title":"Allogeneic hematopoietic cell transplantation for adult T cell acute lymphoblastic leukemia","volume":"23","author":"Hamilton","year":"2017","journal-title":"Biol Blood Marrow Transplant."},{"issue":"1","key":"2022070715214982200_B29","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41375-019-0548-z","article-title":"Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell\/CD19\/CD22-negative acute lymphoblastic leukemia","volume":"34","author":"Ofran","year":"2020","journal-title":"Leukemia."},{"issue":"19","key":"2022070715214982200_B30","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1182\/bloodadvances.2020002502","article-title":"CD1a is rarely expressed in pediatric or adult relapsed\/refractory T-ALL: implications for immunotherapy","volume":"4","author":"Leong","year":"2020","journal-title":"Blood Adv."},{"issue":"1","key":"2022070715214982200_B31","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1600-065X.1998.tb01573.x","article-title":"CD38: a new paradigm in lymphocyte activation and signal transduction","volume":"161","author":"Lund","year":"1998","journal-title":"Immunol Rev."},{"issue":"13","key":"2022070715214982200_B32","doi-asserted-by":"crossref","first-page":"e99442","DOI":"10.1172\/jci.insight.99442","article-title":"TCR\u03b1\u03b2\/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy","volume":"3","author":"Rasaiyaah","year":"2018","journal-title":"JCI Insight."},{"issue":"3","key":"2022070715214982200_B33","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/leu.2015.311","article-title":"Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells","volume":"30","author":"Pinz","year":"2016","journal-title":"Leukemia."},{"issue":"8","key":"2022070715214982200_B34","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","article-title":"A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies","volume":"126","author":"Mamonkin","year":"2015","journal-title":"Blood."},{"issue":"25","key":"2022070715214982200_B35","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/bloodadvances.2017009928","article-title":"Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies","volume":"1","author":"Png","year":"2017","journal-title":"Blood Adv."},{"issue":"9","key":"2022070715214982200_B36","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","article-title":"Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia","volume":"131","author":"Bride","year":"2018","journal-title":"Blood."},{"issue":"21","key":"2022070715214982200_B37","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1182\/blood-2018-10-882944","article-title":"Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia","volume":"133","author":"S\u00e1nchez-Mart\u00ednez","year":"2019","journal-title":"Blood."},{"issue":"30","key":"2022070715214982200_B38","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial","volume":"39","author":"Pan","year":"2021","journal-title":"J Clin Oncol."},{"key":"2022070715214982200_B39","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood-2019-129559","article-title":"Safety and anti-tumor activity of CD5 CAR T-cells in patients with relapsed\/refractory T-cell malignancies","volume":"134","author":"Hill","year":"2019","journal-title":"Blood."},{"issue":"5","key":"2022070715214982200_B40","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1084\/jem.192.5.761","article-title":"Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity","volume":"192","author":"Kunkel","year":"2000","journal-title":"J Exp Med."},{"issue":"1","key":"2022070715214982200_B41","doi-asserted-by":"crossref","first-page":"134","DOI":"10.4049\/jimmunol.168.1.134","article-title":"Characterization of CCR9 expression and CCL25\/thymus-expressed chemokine responsiveness during T cell development: CD3(high)CD69+ thymocytes and gammadeltaTCR+ thymocytes preferentially respond to CCL25","volume":"168","author":"Uehara","year":"2002","journal-title":"J Immunol."},{"issue":"15","key":"2022070715214982200_B42","doi-asserted-by":"crossref","first-page":"6347","DOI":"10.1073\/pnas.0609180104","article-title":"CCR9 is a homing receptor for plasmacytoid dendritic cells to the small intestine","volume":"104","author":"Wendland","year":"2007","journal-title":"Proc Natl Acad Sci USA."},{"issue":"3","key":"2022070715214982200_B43","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1084\/jem.20030996","article-title":"Chemokine receptor CCR9 contributes to the localization of plasma cells to the small intestine","volume":"199","author":"Pabst","year":"2004","journal-title":"J Exp Med."},{"issue":"8","key":"2022070715214982200_B44","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1172\/JCI0215988","article-title":"CCL25 mediates the localization of recently activated CD8alphabeta(+) lymphocytes to the small-intestinal mucosa","volume":"110","author":"Svensson","year":"2002","journal-title":"J Clin Invest."},{"issue":"5","key":"2022070715214982200_B45","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1586\/1744666X.2.5.759","article-title":"Role of CCL25\/CCR9 in immune homeostasis and disease","volume":"2","author":"Svensson","year":"2006","journal-title":"Expert Rev Clin Immunol."},{"issue":"4","key":"2022070715214982200_B46","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1182\/blood.V97.4.850","article-title":"Expression of CCR9 beta-chemokine receptor is modulated in thymocyte differentiation and is selectively maintained in CD8(+) T cells from secondary lymphoid organs","volume":"97","author":"Carramolino","year":"2001","journal-title":"Blood."},{"key":"2022070715214982200_B47","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jaut.2016.01.001","article-title":"Intestinal CCL25 expression is increased in colitis and correlates with inflammatory activity","volume":"68","author":"Trivedi","year":"2016","journal-title":"J Autoimmun."},{"key":"2022070715214982200_B48","first-page":"119","article-title":"CCR9 antagonism: potential in the treatment of inflammatory bowel disease","volume":"8","author":"Wendt","year":"2015","journal-title":"Clin Exp Gastroenterol."},{"issue":"10","key":"2022070715214982200_B49","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/apt.13398","article-title":"Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn\u2019s disease","volume":"42","author":"Feagan","year":"2015","journal-title":"Aliment Pharmacol Ther."},{"issue":"1","key":"2022070715214982200_B50","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/icvts\/ivu343","article-title":"Routine thymectomy in congenital cardiac surgery changes adaptive immunity without clinical relevance","volume":"20","author":"Roosen","year":"2015","journal-title":"Interact Cardiovasc Thorac Surg."},{"issue":"5","key":"2022070715214982200_B51","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/path.3015","article-title":"Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia","volume":"226","author":"Mirandola","year":"2012","journal-title":"J Pathol."},{"issue":"10","key":"2022070715214982200_B52","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1172\/JCI61269","article-title":"The molecular basis of T cell acute lymphoblastic leukemia","volume":"122","author":"Van Vlierberghe","year":"2012","journal-title":"J Clin Invest."},{"issue":"20","key":"2022070715214982200_B53","doi-asserted-by":"crossref","first-page":"7579","DOI":"10.1158\/0008-5472.CAN-04-0641","article-title":"CC chemokine ligand 25 enhances resistance to apoptosis in CD4+ T cells from patients with T-cell lineage acute and chronic lymphocytic leukemia by means of livin activation","volume":"64","author":"Qiuping","year":"2004","journal-title":"Cancer Res."},{"issue":"4","key":"2022070715214982200_B54","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.4161\/mabs.29063","article-title":"Antitumor effects of a monoclonal antibody to human CCR9 in leukemia cell xenografts","volume":"6","author":"Chamorro","year":"2014","journal-title":"MAbs."},{"issue":"12","key":"2022070715214982200_B55","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov."},{"issue":"5","key":"2022070715214982200_B56","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the antigen density requirement for CAR T-cell activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov."},{"issue":"8","key":"2022070715214982200_B57","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med."},{"issue":"10297","key":"2022070715214982200_B58","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet."},{"issue":"18","key":"2022070715214982200_B59","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med."},{"issue":"7","key":"2022070715214982200_B60","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood-2017-05-781351","article-title":"An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma","volume":"131","author":"Lee","year":"2018","journal-title":"Blood."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/1\/25\/1905442\/bloodbld2021013648.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/1\/25\/1905442\/bloodbld2021013648.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T11:23:03Z","timestamp":1657192983000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/140\/1\/25\/485152\/Anti-CCR9-chimeric-antigen-receptor-T-cells-for-T"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,7]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,7,7]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021013648","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,7]]}}}